AZNCF News and Press, AstraZeneca Plc From 05/08/20

Previously, I wrote how indiscriminate buying would be replaced with selectivity and that the market was approaching an important make-or-break moment following its rapid run-up since March. The S&P 500 remains below critical resistance, so the risk of weakness remains. However, our ...

Avrobio Collaborates with Magenta Therapeutics for Advancing Novel ADC Avrobio Inc. ( AVRO ) announced its latest collaboration with Magenta Therapeutics ( MGTA ) for advancing the latter's lead drug candidate MGTA-117. The tie-up will provide synergies for both the companies as Avrobio pr...

Starpharma VivaGel antiviral condom launched in Japan under Okamoto 003 brand Last month I wrote an article suggesting that Starpharma’s (OTCQX: OTCQX:SPHRY ) share price has been savaged by COVID-19 for no good reason. Now Starpharma is showing signs of fighting back against ...

Investment Thesis The stakes have never been higher for Moderna, Inc. ( MRNA ) as it battles a myriad of competitors in the race for a successful COVID-19 vaccine. The long and arduous process of vaccine development and testing has slim monetary gains and a low chance of success. Despite a...

Substantial fiscal and monetary intervention has fueled a dramatic run-up in shares; however, the market is approaching resistance, suggesting a make-or-break moment for the recent rally is approaching. Specifically, the S&P 500 is almost back to its 200-day moving average (DMA), raisi...

AstraZeneca PLC (AZN) Q1 2020 Earnings Conference Call April 29, 2020, 06:45 AM ET Company Participants Pascal Soriot - Chief Executive Officer Dave Fredrikson - Executive Vice President, Oncology Ruud Dobber - Executive Vice President, BioPharmaceutical Marc Dunoyer - Chief Fi...

The following slide deck was published by AstraZeneca PLC in conjunction with their 2020 Q1 earnings Read more ...

Quick Take ORIC Pharmaceuticals ( ORIC ) intends to raise $75 million in an IPO of its common stock, per an amended S-1/A registration statement . The company is advancing a pipeline of drug candidates for the treatment of prostate cancer and solid tumors. ORIC is led by extremely capab...

Quick Take Lantern Pharma ( LTRN ) has filed to raise $28.75 million in an IPO of its common stock, according to an S-1 registration statement . The firm is developing a pipeline of drug candidates for the treatment of prostate, lung and other cancers. LTRN seeks to use its proprietary ...

Sangamo Closes Gene Collaboration with Biogen Sangamo Therapeutics ( SGMO ) reported that it has finalized its sale of stock to Biogen ( BIIB ), leading to the formal initiation of its global licensing collaboration with latter. The collaboration pertains to gene regulation therapies in ...